Mitochondrial Diseases clinical trials at UCSD
3 in progress, 1 open to eligible people
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
open to all eligible people
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
San Diego, California and other locations
Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Sorry, in progress, not accepting new patients
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.
La Jolla, California and other locations
Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Sorry, in progress, not accepting new patients
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).
San Diego, California and other locations
Our lead scientists for Mitochondrial Diseases research studies include Robert Naviaux, MD Richard Haas, MD PhD.
Last updated: